Autor: |
Pluimakers, Vincent1 (AUTHOR), Fiocco, Marta1,2,3 (AUTHOR), Atteveld, Jenneke van1 (AUTHOR), Hobbelink, Monique4 (AUTHOR), Bresters, Dorine1 (AUTHOR), Broeder, Eline Van Dulmen-den1,5 (AUTHOR), Loo, Margriet Van der Heiden-van der6 (AUTHOR), Janssens, Geert O1,4 (AUTHOR), Kremer, Leontien1,5 (AUTHOR), Loonen, Jacqueline7 (AUTHOR), Louwerens, Marloes2 (AUTHOR), Pal, Helena Van der1 (AUTHOR), Ronckers, Cécile1,5,8 (AUTHOR), Santen, Hanneke Van1,9 (AUTHOR), Versluys, Birgitta1,9 (AUTHOR), Vries, Andrica De1,10 (AUTHOR), Heuvel-Eibrink, Marry Van den1 (AUTHOR), Neggers, Sebastian1,11 (AUTHOR) |
Zdroj: |
Journal of Medical Internet Research. Jan2021, Vol. 23 Issue 1, pN.PAG-N.PAG. 1p. 2 Charts. |
Abstrakt: |
Background: Potential late effects of treatment for childhood cancer include adiposity, insulin resistance, dyslipidemia, and hypertension. These risk factors cluster together as metabolic syndrome and increase the risk for development of diabetes mellitus and cardio- and cerebrovascular disease. Knowledge on risk factors, timely diagnosis, and preventive strategies is of importance to prevent cardio- and cerebrovascular complications and improve quality of life. Currently, no national cohort studies on the prevalence and determinants of metabolic syndrome in childhood cancer survivors, including biomarkers and genetic predisposition, are available. Objective: The objectives of the Dutch LATER METS study are to assess 1) the prevalence and risk factors of metabolic syndrome and its separate components, and 2) the potential diagnostic and predictive value of additional biomarkers for surveillance of metabolic syndrome in the national cohort of adult long-term survivors of childhood cancer. Methods: This is a cross-sectional study based on recruitment of all survivors treated in the Netherlands between 1963 and 2002. Metabolic syndrome will be classified according to the definitions of the third Adult Treatment Panel Report of the National Cholesterol Education Program as well as the Joint Interim Statement and compared to reference data. Dual-energy x-ray absorptiometry scans were performed to assess body composition in more detail. The effect of patient characteristics, previous treatment, and genetic variation on the risk of metabolic syndrome will be assessed. The diagnostic and predictive value of novel biomarkers will be tested. Results: Patient accrual started in 2016 and lasted until April 2020. A total of 2380 survivors from 7 pediatric oncology hospitals have participated. From July 2020, biomarker testing, single nucleotide polymorphism analysis, and data analysis will be performed. Conclusions: The Dutch LATER METS study will provide knowledge on clinical and genetic determinants of metabolic syndrome and the diagnostic value of biomarkers in childhood cancer survivors. The results of this study will be used to optimize surveillance guidelines for metabolic syndrome in survivors based on enhanced risk stratification and screening strategies. This will improve diagnosis of metabolic syndrome and prevent complications. International Registered Report Identifier (IRRID): DERR1-10.2196/21256 JMIR Res Protoc 2021;10(1):e21256 doi:10.2196/21256 We help JMIR researchers to raise funds to pursue their research and development aimed at tackling important health and technology challenges. If you would like to show your support for this author, please donate using the button below. The funds raised will directly benefit the corresponding author of this article (minus 8% admin fees). Your donations will help this author to continue publishing open access papers in JMIR journals. Donations of over $100 may also be acknowledged in future publications. Suggested contribution levels: $20/$50/$100 [ABSTRACT FROM AUTHOR] |
Databáze: |
Library, Information Science & Technology Abstracts |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|